Galmed Pharmaceuticals Ltd. reported its quarterly financial results, revealing a net loss of $1.9 million for Q3 2024 and a total cash and cash equivalents of $9.7 million as of September 30, 2024. The filing is significant as it highlights the company's ongoing financial challenges, with an accumulated deficit of $197.3 million and a need for additional capital to fund operations and development projects.